BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 34174340)

  • 1. Long non-coding RNAs correlate with genomic stability in prostate cancer: A clinical outcome and survival analysis.
    Jianfeng W; Yutao W; Jianbin B
    Genomics; 2021 Sep; 113(5):3141-3151. PubMed ID: 34174340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of bladder cancer outcome by identifying and validating a mutation-derived genomic instability-associated long noncoding RNA (lncRNA) signature.
    Wu H; Zhang ZY; Zhang Z; Xiao XY; Gao SL; Lu C; Zuo L; Zhang LF
    Bioengineered; 2021 Dec; 12(1):1725-1738. PubMed ID: 33955803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and validation of a novel eight mutant-derived long non-coding RNAs signature as a prognostic biomarker for genome instability in low-grade glioma.
    Maimaiti A; Wang X; Pei Y; Nuermaimaiti N; Tuersunniyazi A; Abula Y; Feng Z; Jiang L; Shi X; Kasimu M
    Aging (Albany NY); 2021 Jun; 13(11):15164-15192. PubMed ID: 34081618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutator-Derived lncRNA Landscape: A Novel Insight Into the Genomic Instability of Prostate Cancer.
    Tang L; Li W; Xu H; Zheng X; Qiu S; He W; Wei Q; Ai J; Yang L; Liu J
    Front Oncol; 2022; 12():876531. PubMed ID: 35860569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction of a genome instability-derived lncRNA-based risk scoring system for the prognosis of hepatocellular carcinoma.
    Huang DP; Liao MM; Tong JJ; Yuan WQ; Peng DT; Lai JP; Zeng YH; Qiu YJ; Tong GD
    Aging (Albany NY); 2021 Nov; 13(22):24621-24639. PubMed ID: 34799469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational identification of mutator-derived lncRNA signatures of genome instability for improving the clinical outcome of cancers: a case study in breast cancer.
    Bao S; Zhao H; Yuan J; Fan D; Zhang Z; Su J; Zhou M
    Brief Bioinform; 2020 Sep; 21(5):1742-1755. PubMed ID: 31665214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A computational prognostic model of lncRNA signature for clear cell renal cell carcinoma with genome instability.
    Cui T; Guo J; Sun Z
    Expert Rev Mol Diagn; 2022 Feb; 22(2):213-222. PubMed ID: 34871123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation-Derived Long Noncoding RNA Signature Predicts Survival in Lung Adenocarcinoma.
    Yang L; Guo G; Yu X; Wen Y; Lin Y; Zhang R; Zhao D; Huang Z; Wang G; Yan Y; Zhang X; Chen D; Xing W; Wang W; Zeng W; Zhang L
    Front Oncol; 2022; 12():780631. PubMed ID: 35372012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome instability-related LINC02577, LINC01133 and AC107464.2 are lncRNA prognostic markers correlated with immune microenvironment in pancreatic adenocarcinoma.
    Zhang Y; Wang Y; He X; Yao R; Fan L; Zhao L; Lu B; Pang Z
    BMC Cancer; 2023 May; 23(1):430. PubMed ID: 37173624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long noncoding RNA in prostate, bladder, and kidney cancer.
    Martens-Uzunova ES; Böttcher R; Croce CM; Jenster G; Visakorpi T; Calin GA
    Eur Urol; 2014 Jun; 65(6):1140-51. PubMed ID: 24373479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of 10 differently expressed lncRNAs as prognostic biomarkers for prostate adenocarcinoma.
    Wu ZY; Wang SG; Li Q; Zhao QS; Shao MM
    Math Biosci Eng; 2019 Dec; 17(3):2037-2047. PubMed ID: 32233522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular network-based identification of competing endogenous RNAs and mRNA signatures that predict survival in prostate cancer.
    Xu N; Wu YP; Yin HB; Xue XY; Gou X
    J Transl Med; 2018 Oct; 16(1):274. PubMed ID: 30286759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic instability-associated lncRNA signature predicts prognosis and distinct immune landscape in gastric cancer.
    Sun J; Jiang Q; Chen H; Zhang Q; Zhao J; Li H; Wang X; Fang Y; Ruan Y; Sun Y
    Ann Transl Med; 2021 Aug; 9(16):1326. PubMed ID: 34532463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Excavating novel diagnostic and prognostic long non-coding RNAs (lncRNAs) for head and neck squamous cell carcinoma: an integrated bioinformatics analysis of competing endogenous RNAs (ceRNAs) and gene co-expression networks.
    Yang L; Lu P; Yang X; Li K; Chen X; Qu S
    Bioengineered; 2021 Dec; 12(2):12821-12838. PubMed ID: 34898376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of potential autophagy-associated lncRNA in prostate cancer.
    Li J; Du H; Chen W; Qiu M; He P; Ma Z
    Aging (Albany NY); 2021 May; 13(9):13153-13165. PubMed ID: 33971627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational detection of a genome instability-derived lncRNA signature for predicting the clinical outcome of lung adenocarcinoma.
    Guo CR; Mao Y; Jiang F; Juan CX; Zhou GP; Li N
    Cancer Med; 2022 Feb; 11(3):864-879. PubMed ID: 34866362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioinformatic identification of genomic instability-associated lncRNAs signatures for improving the clinical outcome of cervical cancer by a prognostic model.
    Zhang J; Ding N; He Y; Tao C; Liang Z; Xin W; Zhang Q; Wang F
    Sci Rep; 2021 Oct; 11(1):20929. PubMed ID: 34686717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computational epigenetic landscape analysis reveals association of CACNA1G-AS1, F11-AS1, NNT-AS1, and MSC-AS1 lncRNAs in prostate cancer progression through aberrant methylation.
    Tonmoy MIQ; Fariha A; Hami I; Kar K; Reza HA; Bahadur NM; Hossain MS
    Sci Rep; 2022 Jun; 12(1):10260. PubMed ID: 35715447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic analysis of lncRNA-miRNA-mRNA competing endogenous RNA network identifies four-lncRNA signature as a prognostic biomarker for breast cancer.
    Fan CN; Ma L; Liu N
    J Transl Med; 2018 Sep; 16(1):264. PubMed ID: 30261893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long non-coding RNA profile study identifies an immune-related lncRNA prognostic signature for prostate adenocarcinoma.
    Liang L; Xia W; Yao L; Wu Q; Hua L; Cheng G; Wang Z; Zhao R
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108267. PubMed ID: 34740081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.